Furthermore, DADS treatment enhanced the inhibitory effect of GSK2795039 (an inhibitor of NADPH oxidase 2) on ROS production in CRC cells (P<0.05, Figure 2G), indicating that DADS treatment did not promote ROS production to induce DNA damage in CRC cells. Here, CYBB is linked to colorectal carcinoma.